Sector News

Novartis poaches Roche’s neuro and rare disease R&D lead, replacing Shanker

December 12, 2021
Life sciences

Novartis has been busy selling off its stake in Roche but quietly this month also got a little extra from its fellow Swiss native after nabbing Bob Baloh, M.D., Ph.D., to run its growing neuroscience division.

Baloh joins the company as Novartis Institutes for BioMedical Research’s (NIBR’s) global head of the neuroscience disease area. He comes from a similar position at Roche, where he served as vice president and global head of research in neuroscience and rare diseases in the Pharmaceutical Research and Early Development division.

He had a relatively short stint at Roche—just a year—but spent nearly a decade before that at the Cedars-Sinai Medical Center in California as a renowned neurodegeneration and peripheral nervous system disease expert as well as a passionate physician-scientist.

Novartis also tells me he is a talented surfer, and that skill will be needed to ride the choppy waves of neuro that have caused so many to wipe out.

He comes amid a loss of neuro talent from the Big Pharma, and takes over from Gopi Shanker, Ph.D., who had been the NIBR’s head of neuroscience before leaving in May for a transfer-RNA-based gene therapy startup.

At Novartis, Baloh will help work on a host of diseases and disorders in a field beset with setbacks for the industry but containing some of human biology’s biggest unsolved problems.

Novartis is currently working on new therapies for spinal muscular atrophy, Rett syndrome, autism spectrum disorders, intellectual disabilities and epileptic encephalopathies as well as bipolar disorder, depression, substance use disorders and schizophrenia.

It’s also got its eyes on Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and several rare monogenic diseases along with multiple sclerosis.

by Ben Adams

Source: fiercebiotech.com

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend